Efaproxiral

Summary

Efaproxiral (CHEMBL18901) is a phase-3 clinical-stage small molecule (ATC L01XD06); indicated across 4 conditions including neoplasm and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: L01XD06
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 341.4 Da · C20H23NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL18901
Name	Efaproxiral
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	122335
ATC	L01XD06
Molecular formula	C20H23NO4
Molecular weight	341.4
InChIKey	BNFRJXLZYUTIII-UHFFFAOYSA-N

SMILES: CC1=CC(=CC(=C1)NC(=O)CC2=CC=C(C=C2)OC(C)(C)C(=O)O)C

IUPAC name: 2-[4-[2-(3,5-dimethylanilino)-2-oxoethyl]phenoxy]-2-methylpropanoic acid

Also known as: Efaproxiral, RSR-13, RSR13, EFAPROXIRAL

Parent form; salt/anhydrous children: CHEMBL2107744

Patent coverage: 406 distinct patent families (924 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
neoplasm	3	MONDO:0005070	EFO:0000616
breast neoplasm	3	MONDO:0021100	MONDO:0007254
lung neoplasm	3	MONDO:0021117	MONDO:0008903
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00005887	PHASE3	COMPLETED	Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
NCT00055887	PHASE3	WITHDRAWN	Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00083304	PHASE3	COMPLETED	Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer
NCT00004202	PHASE2	COMPLETED	Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00005855	PHASE1/PHASE2	COMPLETED	Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).